**Introduction**

The BTS guideline for the use of home oxygen in adults in the UK was published in June 2015. This offers an evidence-base for the use of different oxygen modalities with outcomes such as mortality, symptoms and quality of life. This pull-out is a quick reference guide for key recommendations for home oxygen provision for the primary care physician. It includes discussion of long-term oxygen therapy (LTOT >15 hours per day), ambulatory oxygen therapy (AOT), nocturnal oxygen therapy (NOT), short-burst oxygen therapy (SBOT) and palliative oxygen therapy (POT).

**The Use of Palliative Oxygen**

Oxygen might be of use in end-stage cardiorespiratory or malignant disease as POT after the trial of other evidence-based interventions

- Fan therapy or opiates (rather than oxygen) should be used initially for intractable breathlessness with saturations >92%.
- Specialist referral might be made in persistent dyspnoea unresponsive to conventional therapies for consideration of POT.

**Assessment for Oxygen and Withdrawal of Oxygen**

- Assessment, withdrawal and review of oxygen provision all carried out by relevant Home Oxygen assessment services (HOAS).
- Two ABGs taken three weeks apart.
- Oxygen supply may include up-titration of oxygen flow rates at night or on exercise, on balance with possible risk of rise in CO2.
- HOAS decide on risk of oxygen provision in smokers. There is limited clinical benefit for LTOT in smokers.
- Reassessment at 6 months and thereafter annually.
- Oxygen will be withdrawn if criteria no longer met.
- If oxygen is provided on discharge due to clinical instability (rare), oxygen withdrawal might occur at follow-up within 8 weeks of hospital discharge.

**Oxygen Use in Other Circumstances**

- Pulmonary hypertension with saturations <94% may benefit from LTOT.
- Heart failure patients might be eligible for LTOT if saturations are <92% (or <94% with signs of pulmonary hypertension).
- Heart failure patients not meeting LTOT criteria with evidence of sleep disordered breathing (without signs of obesity hypoventilation or obstructive sleep apnoea) may consider NOT.
- AOT may be considered to improve exercise tolerance in ILD patients (with marked exertional dyspnoea) even if LTOT not required. There is no evidence for NOT in ILD.
- AOT may be appropriate for Cystic Fibrosis patients with exertional desaturation (>4% to <90% on exercise), not meeting LTOT criteria. Usually done by respective CF centre. NOT in CF should only be prescribed in combination with nocturnal ventilatory support.
- SBOT has excellent evidence-base in cluster headache. There is usually sufficient prodrome to allow SBOT provision to be made as an emergency delivery.

**The Use of Oxygen in COPD**

- Home oxygen showed survival benefit when used for >15 hours per day in a selected subgroup of COPD patients (pO2 <8 (sats 94%) with signs of pulmonary hypertension or <7 3 kPa (sats 92%).
- Aim to reach a target PO2 of >8kPa.
- Refer following a period of clinical stability of 8 weeks, all medically optimised patients (on maximal inhaled therapy, post-pulmonary rehabilitation and following appropriate stop smoking treatment) with saturations <92%.
- Monitor saturations annually in all patients with saturations 93-94%.
- LTOT patients may benefit from AOT if they are mobile out-of-doors to aid with exertional hypoxia or dyspnoea.
- SBOT is unsuitable for those individuals not meeting LTOT criteria.
- AOT should only be considered for COPD patients unsuitable for LTOT after proving benefit to exercise tolerance.
- Patients with nocturnal desaturation (not on LTOT), alternative diagnoses such as obstructive sleep apnoea, obesity hypoventilation syndrome or neuromuscular disease should be sought, possibly with referral to home ventilation services.
- There is no role for NOT in COPD patients not needing LTOT.
The cost effective way to ensure you are delivering high value patient centred respiratory care

- Easy access to a wealth of online resources - written by primary care experts for primary care clinicians, saving you time and ideal tools to use with your respiratory team
- Primary Care Respiratory Update, the PCRS-UK members publication bringing you an overview of the latest respiratory research and policy as well as commentary on the latest developments and examples best practice
- Electronic membership mailings and news alerts making it easy to keep up to date
- Support with your own professional development
- Access to a friendly community of like-minded peers passionate about respiratory care
- Access to exclusive member-only events
- Annual membership just £59 inclusive of VAT - plus huge savings on registration for our annual national primary care conference

It pays to join if you are a respiratory lead for your practice or a respiratory healthcare professional working in the community!

Contact info@pcrs-uk to find out about discounts available to CCGs, health boards, community teams or other groups wishing to buy 10+ memberships.

The Primary Care Respiratory Society UK (PCRS-UK) welcomes affiliation with any local respiratory group or network. As an affiliated group you will continue to operate independently of PCRS-UK. The group/network will, however, be able to promote that it is affiliated to PCRS-UK.

Features and benefits of affiliation

- Raise your group’s profile locally through enhanced credibility by being associated with a nationally recognised professional society
- Use PCRS-UK logo on your materials*
- Details of your group included on our website to encourage new group members/attendees at meetings
- Promote your events via emails to local members and be listed on our events page
- Quarterly newsletter for group leaders featuring ideas and tips to take back to your group
- FREE membership to PCRS-UK for group leader giving you access to regular updates and a wealth of resources that can be used to help facilitate discussion at meetings and support improved care locally
- Opportunity to attend annual meeting of group/network leaders for training, support, networking and information relevant to your role as a group leader

The PCRS-UK is grateful to Napp Pharmaceuticals for the provision of an educational grant to support the activities of the Affiliated Group Leaders programme in 2015. Subject to terms and conditions of affiliation.

For more information or to arrange a call with an existing group leader to learn more about the benefits of affiliation email us at tricia@pcrs-uk.org.

The Public Care Respiratory Society UK is grateful to its corporate supporters including AstraZeneca UK Ltd, Boehringer Ingelheim Ltd, Chiesi Ltd, GlaxoSmithKline, Napp Pharmaceuticals, Novartis UK, Pfizer Ltd and TEVA UK Limited for their financial support which supports the core activities of the Charity and allows PCRS-UK to make its services either freely available or at greatly reduced rates to its members.


Join the PCRS-UK http://www.pcrs-uk.org/join

Inspiring best practice in respiratory care